Array ( [0] => 23810 [1] => 23808 [2] => 23632 ) Array ( [0] => 23810 [1] => 23808 [2] => 23632 ) Array ( [0] => 29041 [1] => 28962 [2] => 21543 ) Array ( [0] => 29041 [1] => 28962 [2] => 21543 )

Last Updated: 27/10/2022

A study to determine if a new Malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants.

Objectives

To evaluate the safety and immunogenicity of different doses of a candidate Malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya.

Principal Institution

University of Oxford, United Kingdom

Principal Investigators / Focal Persons

Adrian VS Hill

Partner Institutions

European and Developing Countries Clinical Trials Partnership (EDCTP), The Netherlands
Kenya Medical Research Institute (KEMRI), Kenya

Rationale and Abstract

This is a clinical trial to evaluate the safety and immunogenicity of R21/MM in healthy Kenyan participants from the different age groups.

The study includes three age groups:

Group 1: healthy adults (18-45 years)

Group 2: young children (aged 1-5 years)

Group 3: infants (aged 5- <12 months of age)